- Home
- SDHC vs SPRY Comparison
SDHC vs SPRY Comparison
Compare SDHC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHC
- SPRY
- Stock Information
- Founded
- SDHC 2008
- SPRY 2015
- Country
- SDHC United States
- SPRY United States
- Employees
- SDHC N/A
- SPRY N/A
- Industry
- SDHC
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- SDHC
- SPRY Health Care
- Exchange
- SDHC Nasdaq
- SPRY Nasdaq
- Market Cap
- SDHC 1.3B
- SPRY 1.1B
- IPO Year
- SDHC 2024
- SPRY N/A
- Fundamental
- Price
- SDHC $25.08
- SPRY $12.57
- Analyst Decision
- SDHC Hold
- SPRY Strong Buy
- Analyst Count
- SDHC 6
- SPRY 4
- Target Price
- SDHC $29.60
- SPRY $26.00
- AVG Volume (30 Days)
- SDHC 161.4K
- SPRY 1.5M
- Earning Date
- SDHC 01-28-2025
- SPRY 11-13-2024
- Dividend Yield
- SDHC N/A
- SPRY N/A
- EPS Growth
- SDHC N/A
- SPRY N/A
- EPS
- SDHC 4.71
- SPRY N/A
- Revenue
- SDHC $905,304,000.00
- SPRY $2,568,000.00
- Revenue This Year
- SDHC $27.04
- SPRY $66,750.00
- Revenue Next Year
- SDHC $14.47
- SPRY $508.63
- P/E Ratio
- SDHC $5.33
- SPRY N/A
- Revenue Growth
- SDHC 17.46
- SPRY 8460.00
- 52 Week Low
- SDHC $20.55
- SPRY $6.00
- 52 Week High
- SDHC $39.50
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- SDHC 38.98
- SPRY 58.86
- Support Level
- SDHC $21.99
- SPRY $11.00
- Resistance Level
- SDHC $25.31
- SPRY $12.48
- Average True Range (ATR)
- SDHC 0.98
- SPRY 0.81
- MACD
- SDHC 0.24
- SPRY 0.28
- Stochastic Oscillator
- SDHC 54.88
- SPRY 84.95
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. The company has organized into five geographical segments so their reportable segments include Atlanta, Raleigh, Charlotte, Nashville, and Alabama which consists of both Birmingham and Huntsville.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.